Welcome to our dedicated page for NewAmsterdam Pharma Co N.V. SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pharma Co N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pharma Co N.V.'s regulatory disclosures and financial reporting.
NewAmsterdam Pharma Company N.V. reported first‑quarter 2026 results showing it remains a late‑stage, R&D‑focused biopharma with no approved products and ongoing losses. Revenue was modest at $3.0 million, coming mainly from product supply under the Menarini agreement.
Research and development spending was $38.0 million, down from the prior year as several Phase 3 LDL‑C trials completed, while selling, general and administrative expenses fell to $23.5 million. The company recorded a net loss of $48.4 million, or $0.40 per share.
Cash, cash equivalents and marketable securities totaled $707.3 million, supporting continued investment in the large PREVAIL cardiovascular outcomes trial and other studies of obicetrapib, including work on a fixed‑dose combination with ezetimibe and exploration in Alzheimer’s disease and diabetes‑related indications.
FMR LLC files an amendment to Schedule 13G reporting beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV common stock. The filing states FMR LLC holds 8,765,811 shares, representing 7.6% of the class, with sole dispositive power and no shared voting power reported. The amendment notes related power-of-attorney authority and references Exhibit 99 and an Exhibit 24 power of attorney.
NewAmsterdam Pharma Company N.V. is asking shareholders to vote at its June 2, 2026 annual general meeting in Amsterdam on nine proposals covering financial statements, governance and compensation.
Shareholders are asked to adopt the Dutch statutory annual accounts for 2025, discharge directors from liability for 2025, and instruct and ratify Deloitte Accountants B.V. as external auditor and independent registered public accounting firm for 2026. Two non-executive directors, John W. Smither and Janneke van der Kamp, are up for reappointment with proposed terms running until the 2030 annual meeting.
The agenda also seeks to extend the Board’s authority to issue ordinary shares and to limit or exclude pre-emption rights for up to five years, approve a 2026 Employee Stock Purchase Plan reserving 1,150,000 ordinary shares, and hold a non-binding advisory vote on 2025 compensation for named executive officers. Shareholders of record as of May 5, 2026 may vote in person, by proxy, telephone or internet, subject to the described deadlines and procedures.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Company N.V. is soliciting proxies for its 2026 Annual General Meeting to be held on June 2, 2026 at 5:00 p.m. CEST in Amsterdam. The agenda includes adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2025, discharge of directors, auditor instruction and ratification, director reappointments, extensions of authorizations to issue ordinary shares and to limit pre-emption rights, approval of a 2026 Employee Stock Purchase Plan (ESPP) reserving 1,150,000 ordinary shares, and a non-binding advisory vote on 2025 executive compensation.
The Record Date is May 5, 2026; Beneficial Owners must submit an Attendance Notice and supporting proof by 11:59 p.m. ET on May 31, 2026 (Cut-off Time). Audit fees paid to Deloitte were $1,071,000 for 2025 and $1,433,000 for 2024. Proxy voting options, quorum rules and vote thresholds for each proposal are described in the proxy materials.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported open-market sales of a total of 44,619 Ordinary Shares on March 11, 2026. He sold 44,173 shares at a weighted average price of $30.41 per share and 446 shares at a weighted average price of $31.23 per share. After these sales, he directly owns 10,360 Ordinary Shares. The prices reflect multiple trades in ranges from $30.11 to $31.31 per share.
NewAmsterdam Pharma Company N.V. resale filing shows planned and recent transfers of Ordinary Shares. The filing lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash. It also records that The LG Lange III Trust sold 28,186 Ordinary Shares on 03/06/2026 for $828,849.41.
This Form 144 excerpt documents resale activity by a trust and a warrant-related issuance; cash‑flow treatment for proceeds beyond the warrant exercise is not detailed in the excerpt.
NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales. On March 9, 2026, he exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, leaving him with 54,979 Ordinary Shares held directly.
Separately, on March 6, 2026, a trust associated with him, the LGLange III Trust DTD10, sold 28,186 Ordinary Shares in open-market transactions at a weighted average price of $29.41 per share, within a range of $29.03 to $29.68, and reported no remaining indirect holdings.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.